Keytruda and Chemotherapy in Advanced Endometrial Cancer
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
Keytruda and Chemotherapy in Advanced Endometrial Cancer
- August 2, 2023
- Reading time: 1 minute
On June 3, 2023, Dr. Ramez N. Eskander and colleagues from the University of California San Diego published the results of the Phase 3 NRG-GY018 trial in The New England Journal of Medicine. The study evaluated the addition of Keytruda (pembrolizumab) to standard first-line chemotherapy for patients with recurrent or advanced endometrial cancer.
Study Design: The NRG-GY018 trial enrolled 816 patients with Stage III, IVA, IVB, or recurrent endometrial cancer. Participants were randomized 1:1 into two groups:
- Keytruda Group: Keytruda plus chemotherapy (up to 6 cycles every three weeks), followed by Keytruda monotherapy as maintenance (up to 14 cycles every six weeks).
- Placebo Group: Standard chemotherapy plus placebo.
The primary endpoint was progression-free survival (PFS), stratified by mismatch-repair-deficient (dMMR) or mismatch-repair-proficient (pMMR) status.
Clinical Outcomes: The trial results showed significant improvements in PFS for the Keytruda group:
- dMMR Patients: The 12-month PFS rate was 74% in the Keytruda group compared to 38% in the placebo group.
- pMMR Patients: The median PFS was 13.1 months in the Keytruda group versus 8.7 months in the placebo group.
Conclusion: Based on the results of the NRG-GY018 trial, Dr. Ramez N. Eskander and the research team concluded that adding Keytruda to first-line chemotherapy significantly improves progression-free survival in patients with recurrent or advanced endometrial cancer.
Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2302312
- Clinical Trial Medications
- Immunotherapy
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1